1. Home
  2. KPTI vs CMCM Comparison

KPTI vs CMCM Comparison

Compare KPTI & CMCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • CMCM
  • Stock Information
  • Founded
  • KPTI 2008
  • CMCM 2009
  • Country
  • KPTI United States
  • CMCM China
  • Employees
  • KPTI N/A
  • CMCM N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • CMCM Computer Software: Prepackaged Software
  • Sector
  • KPTI Health Care
  • CMCM Technology
  • Exchange
  • KPTI Nasdaq
  • CMCM Nasdaq
  • Market Cap
  • KPTI 121.2M
  • CMCM 115.6M
  • IPO Year
  • KPTI 2013
  • CMCM 2014
  • Fundamental
  • Price
  • KPTI $0.86
  • CMCM $4.47
  • Analyst Decision
  • KPTI Strong Buy
  • CMCM
  • Analyst Count
  • KPTI 4
  • CMCM 0
  • Target Price
  • KPTI $5.00
  • CMCM N/A
  • AVG Volume (30 Days)
  • KPTI 886.0K
  • CMCM 64.4K
  • Earning Date
  • KPTI 10-31-2024
  • CMCM 10-24-2024
  • Dividend Yield
  • KPTI N/A
  • CMCM N/A
  • EPS Growth
  • KPTI N/A
  • CMCM N/A
  • EPS
  • KPTI N/A
  • CMCM N/A
  • Revenue
  • KPTI $145,668,000.00
  • CMCM $97,678,928.00
  • Revenue This Year
  • KPTI $6.41
  • CMCM N/A
  • Revenue Next Year
  • KPTI $11.85
  • CMCM N/A
  • P/E Ratio
  • KPTI N/A
  • CMCM N/A
  • Revenue Growth
  • KPTI N/A
  • CMCM N/A
  • 52 Week Low
  • KPTI $0.62
  • CMCM $1.64
  • 52 Week High
  • KPTI $1.95
  • CMCM $6.78
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 58.15
  • CMCM 53.92
  • Support Level
  • KPTI $0.82
  • CMCM $4.30
  • Resistance Level
  • KPTI $0.94
  • CMCM $5.68
  • Average True Range (ATR)
  • KPTI 0.07
  • CMCM 0.43
  • MACD
  • KPTI 0.01
  • CMCM 0.02
  • Stochastic Oscillator
  • KPTI 68.90
  • CMCM 41.71

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About CMCM Cheetah Mobile Inc. each representing fifty (50)

Cheetah Mobile Inc along with its subsidiaries provides comprehensive products and services on PCs and mobile devices. It generates revenue from utility-related business, including advertising services and premium membership services. It also provides multi-cloud management platform and overseas advertising agency service. The company operates in two segments: Internet business, and AI and others. The firm's majority of the revenue is derived from the internet business segment that provides mobile advertising services to advertising customers, as well as selling advertisements and referring user traffic on its mobile and PC platforms. Geographically, it derives the majority of its revenue from the PRC and the rest from Hong Kong, Japan, and the rest of the world.

Share on Social Networks: